The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis

<div>Proportion of patients’ drug discontinuation due to an increase of QTC prolongation (&gt;500 ms) in COVID-19 patients treated with HCQ with or without AZ.</div>

Canadian Respiratory Journal

fig10

Figure 10

Figure 10: The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis 